✓ Translated by DotMD AI Clinical Council Source: Journal of the National Comprehensive Cancer Network : JNCCN • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #39191270 ↗

Phase III Randomized Trial: Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer (N = 1,862)

Original Paper Title: “Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer”

Elena Rostova (AI Quant) Rigor Score

90 / 100

Sample Size (Participants)

N = 1,862

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

The CTS5 model does not accurately predict the risk of late recurrence in HR+, HER2+ BC treated with adjuvant trastuzumab in the N9831 and B-31 trials. This study underlines the need to develop a new prognostic model to better delineate the risk of late recurrence in patients with HR+, HER2+ BC receiving adjuvant trastuzumab.
Study Design & Sample: Phase III Randomized Trial published in Journal of the National Comprehensive Cancer Network : JNCCN (N = 1862 human participants).
Biostatistical Rigor Score: 90/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of the National Comprehensive Cancer Network : JNCCN (2024), this phase iii randomized trial evaluating 1,862 human participants investigated: The Clinical Treatment Score post-5 years (CTS5) is a risk stratification tool used to determine the risk of late recurrence in hormone receptor-positive (HR+), HER2-negative breast cancer (BC). Key clinical takeaway: The CTS5 model does not accurately predict the risk of late recurrence in HR+, HER2+ BC treated with adjuvant trastuzumab in the N9831 and B-31 trials. This study underlines the need to develop a new prognostic model to better delineate the risk of late recurrence in patients with HR+, HER2+...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of the National Comprehensive Cancer Network : JNCCN, 2024-08-26; N = 1862; Rigor 90/100): The CTS5 model does not accurately predict the risk of late recurrence in HR+, HER2+ BC treated with adjuvant trastuzumab in the N9831 and B-31 trials. This study underlines the need to develop a new prognostic model to better delineate the risk of late recurrence in patients with HR+, HER2+ BC receiving adjuvant trastuzumab.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: 3-6oz-biest-2-5-estrogen-cream-estriol-estradiol-estrogen-cream → Rx: biest-5-0-estrogen-cream-3-6oz-estriol-estradiol → Rx: progesterone → Rx: trastuzumab-and-hyaluronidase-oysk → Condition: granular-cell-tumor → Condition: ewings-sarcoma →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 39191270: Phase III Randomized Trial: Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer (N = 1,862)

3 of 3 Free Questions Remaining